Teixeira C, Frederico Tonietto T, Cadaval Gonçalves S, Viegas Cremonese R, Pinheiro de Oliveira R, Savi A, Silvestre Oliveira E, André Cardona Alves F, Fernando Monteiro Brodt S, Hervê Diel Barth J, Santana Machado A, de Campos Balzano P, Gasparetto Maccari J, Brandão Da Silva N
Intensive Care Unit, Moinhos de Vento Hospital, Porto Alegre, Brazil.
Anaesth Intensive Care. 2008 May;36(3):385-90. doi: 10.1177/0310057X0803600310.
Standard clinical practice recommends minimal doses of vasoactive drugs during weaning of patients from mechanical ventilation. However there are currently no clinical data to inform clinicians about whether the use of noradrenaline during weaning predisposes to weaning failure. The objective of this study was to evaluate whether the necessity of the vasopressor noradrenaline in mechanically ventilated patients recovering from septic shock changed the extubation outcome. A total of 656 patients recovering from septic shock on mechanical ventilation were selected from intensive care units in two university hospitals. Patients receiving noradrenaline at the time of weaning and case-controls not taking noradrenaline were matched for age, gender, haemodynamic and ventilatory parameters, aetiology of respiratory failure and APACHE II score. One hundred and forty-five patients who successfully tolerated a spontaneous breathing trial were extubated while on noradrenaline therapy and the reintubation rate was measured. In the noradrenaline group, the mean dose of noradrenaline during initial shock treatment was 0.52+/-0.29 microg/kg/min and 0.12+/-0.10 microg/kg/min during weaning. The reintubation rate was 12/63 (19%) in the noradrenaline group and 15/82 (18.3%) in the control group (P=1.00). Intensive care unit mortality was also similar in both groups (10/63, 15.9%) for noradrenaline patients and (11/82, 13.4%) for control patients (P=0.81). Arterial blood gases and ventilatory and haemodynamic parameters were similar in all patients regardless of weaning success. We did not find that the use of noradrenaline at the time of weaning was associated with extubation failure. Low doses of noradrenaline may not preclude weaning from mechanical ventilation.
标准临床实践建议在患者机械通气撤机期间使用最小剂量的血管活性药物。然而,目前尚无临床数据告知临床医生撤机期间使用去甲肾上腺素是否会导致撤机失败。本研究的目的是评估在感染性休克后接受机械通气的患者中,血管升压药去甲肾上腺素的必要性是否会改变拔管结果。从两家大学医院的重症监护病房中选取了656例感染性休克后接受机械通气的患者。将撤机时接受去甲肾上腺素治疗的患者与未使用去甲肾上腺素的病例对照者在年龄、性别、血流动力学和通气参数、呼吸衰竭病因及急性生理与慢性健康状况评分系统(APACHE II)评分方面进行匹配。145例成功耐受自主呼吸试验的患者在接受去甲肾上腺素治疗时进行了拔管,并测量了再插管率。在去甲肾上腺素组中,初始休克治疗期间去甲肾上腺素的平均剂量为0.52±0.29微克/千克/分钟,撤机期间为0.12±0.10微克/千克/分钟。去甲肾上腺素组的再插管率为12/63(19%),对照组为15/82(18.3%)(P = 1.00)。两组的重症监护病房死亡率也相似,去甲肾上腺素组患者为10/63(15.9%),对照组患者为11/82(13.4%)(P = 0.81)。无论撤机是否成功,所有患者的动脉血气、通气和血流动力学参数均相似。我们未发现撤机时使用去甲肾上腺素与拔管失败有关。低剂量的去甲肾上腺素可能并不妨碍从机械通气撤机。